Related Experiment Video
Updated: Aug 13, 2026
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
Published on: August 25, 2022
Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells
Carola Meier1, Johannes Middelanis, Bianca Wasielewski
1Department of Neuroanatomy and Molecular Brain Research, Ruhr-University Bochum, Germany.
Insights
Human umbilical cord blood cells show promise in treating neonatal brain damage. Transplantation alleviated motor deficits and improved walking behavior in a rat model of cerebral palsy.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Stem Cell Biology
Background:
- Perinatal brain damage, such as hypoxic-ischemic injury, can lead to lifelong neurodevelopmental deficits and motor impairments like cerebral palsy.
- Human umbilical cord blood (HUCB)-derived mononuclear cells (MNCs) contain multipotent stem cells with potential therapeutic applications.
Purpose of the Study:
- To investigate the therapeutic potential of HUCB-MNCs for motor recovery in a neonatal rat model of cerebral hypoxic-ischemic damage.
- To assess the impact of HUCB-MNC transplantation on neurological deficits and cell integration in the damaged brain.
Main Methods:
- A rat model of perinatal brain damage was established using carotid artery ligation and hypoxic exposure on postnatal day 7.
- Intraperitoneal transplantation of HUCB-MNCs was performed on postnatal day 8 in a sham-controlled design.
- Histological, immunohistochemical, and locomotor behavioral analyses (footprint and walking pattern) were conducted on postnatal day 21.
Main Results:
- Neonatal rats subjected to hypoxic-ischemic insult developed severe cerebral damage and contralateral spastic paresis.
- HUCB-MNC transplantation significantly alleviated spastic paresis, restoring normal walking behavior.
- Transplanted MNCs were found to be incorporated into the lesioned brain area without significant transdifferentiation.
Conclusions:
- Intraperitoneal transplantation of HUCB-MNCs is a viable therapeutic strategy for perinatal brain damage in a rat model.
- HUCB-MNCs facilitate motor recovery and neurological improvement by integrating into the damaged brain tissue.
- This study supports the potential of HUCB-MNCs as a treatment for the neurological effects of cerebral palsy.
Abstract:
Brain damage around birth may cause lifelong neurodevelopmental deficits. We examined the therapeutic potential of human umbilical cord blood-derived mononuclear cells containing multipotent stem cells to facilitate motor recovery after cerebral hypoxic-ischemic damage in neonatal rats. Left carotid artery ligation followed by 8% O(2) inhalation for 80 min was performed on postnatal d 7, succeeded by intraperitoneal transplantation of human umbilical cord blood-derived mononuclear cells on postnatal d 8 in a sham-controlled design. Histologic and immunohistochemical analysis on postnatal d 21 revealed that neonates developed severe cerebral damage after the hypoxic-ischemic insult. These animals also suffered from contralateral spastic paresis, as evidenced by their locomotor behavior. After transplantation of human umbilical cord blood-derived mononuclear cells, spastic paresis was largely alleviated, resulting in a normal walking behavior. This "therapeutic" effect was accompanied by the fact that mononuclear cells had entered the brain and were incorporated around the lesion without obvious signs of transdifferentiation. This study demonstrates that intraperitoneal transplantation of human umbilical cord blood-derived mononuclear cells in a rat model of perinatal brain damage leads to both incorporation of these cells in the lesioned brain area and to an alleviation of the neurologic effects of cerebral palsy as assessed by footprint and walking pattern analysis.
